The British Pharmacopoeia (BP) and United States Pharmacopeia (USP) signed a Memorandum of Understanding (MoU) between the two parties in Washington D.C. on Friday 26 July 2019.

The agreement will enable improved collaboration and knowledge sharing between the BP and the USP in a wide area of standards setting for medicines.

One of the features of this agreement is the commitment from both organisations to provide opportunities for exchange of staff and participation in events and joint working. 

This MOU is significant in the context of the UK leaving the EU, indicating closer cooperation with the USP